Evogene holder Recanati now owns 8.6% stake

Amendment No. 2 reports Leon Recanati’s 8.6% beneficial stake in Evogene and details recent block trade purchases under the company’s at-the-market offering facility.

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) shareholder Leon Recanati filed Amendment No. 2 to a Schedule 13D updating how his recent share purchases were executed and confirming his ownership position. Recanati beneficially owns 1,354,836 ordinary shares, including options, representing 8.6% of the outstanding ordinary shares based on 15,801,407 shares outstanding as of July 27, 2026.

The amendment clarifies that he bought 800,000 shares on August 4, 2026 at a weighted average price of $0.50 per share and 460,000 shares on August 11, 2026 at $0.635 per share, for total consideration of approximately $692,100. These purchases were executed as block trades under Evogene's at-the-market offering facility, for which A.G.P./Alliance Global Partners acts as sales agent, using Recanati’s personal funds. Before the August 4 purchases, he held 83,886 shares directly, excluding option shares.

Key Figures

Beneficial ownership: 1,354,836 ordinary shares Ownership percentage: 8.6% Shares outstanding: 15,801,407 ordinary shares +5 more

8 metrics

Beneficial ownership 1,354,836 ordinary shares Beneficially owned by Leon Recanati, including 10,950 shares underlying exercisable options

Ownership percentage 8.6% Percentage of Evogene ordinary shares beneficially owned by Recanati

Shares outstanding 15,801,407 ordinary shares Evogene ordinary shares outstanding as of July 27, 2026, used to calculate ownership percentage

August 4, 2026 purchase 800,000 shares at $0.50 per share Approximate aggregate consideration $400,000 via block trades under ATM facility

August 11, 2026 purchase 460,000 shares at $0.635 per share Aggregate consideration $292,100 via block trades under ATM facility

Total recent purchase consideration $692,100 Aggregate consideration paid by Recanati for the reported share purchases

Options included in beneficial ownership 10,950 shares Ordinary shares underlying options currently exercisable or exercisable within 60 days of August 11, 2026

Pre‑purchase direct holdings 83,886 shares Ordinary shares held directly by Recanati before August 4, 2026 purchases, excluding options

Key Terms

beneficially owned, at-the-market offering facility, block trades, sales agent, +1 more

5 terms

beneficially owned financial

"The percentage of Ordinary Shares beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

at-the-market offering facility financial

"pursuant to the Issuer's at-the-market offering facility, for which A.G.P."

A program that lets a company sell newly issued shares directly into the open market at prevailing prices over time through a broker, rather than all at once. Think of it as a faucet that lets the company draw small, on-demand amounts of cash when needed. Investors care because it provides flexible, lower-cost fundraising but increases the total shares outstanding — which can reduce existing holders’ ownership and may influence the stock price.

block trades financial

"These purchases were made through block trades carried out pursuant to the Issuer's"

A block trade is a single, large buy or sell of shares or bonds arranged privately between big traders rather than piecemeal on the public market. Think of it like buying a whole shipment at once instead of many small shopping trips; it lets large holders move big positions with less immediate disruption but can signal strong buying or selling pressure and cause price swings once the trade is known, so investors watch block trades for clues about market sentiment and liquidity.

sales agent financial

"for which A.G.P./Alliance Global Partners serves as sales agent"

A sales agent is an individual or firm authorized to sell a company’s products or services on its behalf, typically paid by commission or fees rather than a fixed salary. For investors, who a company uses to reach customers and how well those agents perform affects revenue growth and profit margins — like hiring local independent sellers to expand into new neighborhoods without building stores — so agent quality and cost matter to future cash flow and valuation.

Ordinary Shares financial

"Ordinary shares, par value NIS 0.20 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Evogene (EVGN) does Leon Recanati currently beneficially own?

Leon Recanati beneficially owns 8.6% of Evogene’s ordinary shares, corresponding to 1,354,836 shares, based on 15,801,407 ordinary shares outstanding as of July 27, 2026, as reported by Evogene.

How many Evogene (EVGN) shares did Leon Recanati recently purchase and at what prices?

Leon Recanati purchased 800,000 Evogene shares on August 4, 2026 at a weighted average price of $0.50 per share and 460,000 shares on August 11, 2026 at $0.635 per share.

What total amount did Leon Recanati pay for his recent Evogene (EVGN) share purchases?

He paid aggregate consideration of approximately $692,100 for the reported Evogene share purchases: about $400,000 for 800,000 shares and $292,100 for 460,000 shares, all funded from his personal funds.

How were Leon Recanati’s recent Evogene (EVGN) share purchases executed?

The purchases were executed as block trades carried out under Evogene’s at-the-market offering facility, for which A.G.P./Alliance Global Partners serves as sales agent.

What part of Leon Recanati’s Evogene (EVGN) holdings comes from options?

His aggregate beneficial ownership of 1,354,836 Evogene ordinary shares includes 10,950 shares underlying share options that are currently exercisable or become exercisable within 60 days of August 11, 2026.

How many Evogene (EVGN) shares did Leon Recanati hold before the August 4, 2026 purchases?

Before the August 4, 2026 purchases, Leon Recanati held 83,886 Evogene ordinary shares directly, excluding shares underlying exercisable options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:03 AM Accepted by SEC EDGAR 09/11/2026 - 06:01 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Evogene Ltd.

(Name of Issuer)

Ordinary shares, par value NIS 0.20 per share

(Title of Class of Securities)

M4119S187

(CUSIP Number)

Nitsan Deutsch
13 Gad Feinstein Street, Park Rehovot,,
Rehovot, L3, 7638517
972-8-9311900

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/04/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): M4119S187

1

Name of reporting person

RECANATI LEON

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,354,836.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,354,836.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,354,836.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The percentage of Ordinary Shares beneficially owned by the Reporting Person is of Reporting based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Person: Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 31, 2026. The aggregate beneficial ownership includes 10,950 Ordinary Shares underlying share options held by the Reporting Person that are currently exercisable or exercisable within 60 days of August 11, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary shares, par value NIS 0.20 per share
(b)	Name of Issuer: Evogene Ltd.
(c)	Address of Issuer's Principal Executive Offices: 13 Gad Feinstein Street, Park Rehovot, Rehovot, ILLINOIS , 7638517.
Item 1 Comment: The following constitutes Amendment No. 2 ("Amendment No. 2") to Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") by the Reporting Person on August 11, 2026 (the "Original Statement"), as amended and supplemented by Amendment No. 1 to the Original Statement, filed by the Reporting Person with the SEC on August 13, 2026 ("Amendment No. 1" and together with the Original Statement, the "Schedule 13D"). This Amendment No. 2 is being filed solely to amend the description of the manner of purchase of the Ordinary Shares in Items 3 and 5 of the Schedule 13D, to reflect that the purchases were effected through block trades carried out pursuant to the Issuer's at-the-market offering facility, for which A.G.P./Alliance Global Partners serves as sales agent. Each capitalized term used and not defined herein shall have the meaning assigned to such term in the Schedule 13D. Except as provided herein, each Item of the Schedule 13D remains unchanged.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: The aggregate consideration paid by the Reporting Person for the Ordinary Shares reported herein was approximately $692,100, representing the purchase by the Reporting Person of (i) 800,000 Ordinary Shares on August 4, 2026, at a weighted average price of $0.50 per share (approximately $400,000 in the aggregate), and (ii) an additional 460,000 Ordinary Shares on August 11, 2026, at a purchase price of $0.635 per share ($292,100 in the aggregate). These purchases were made through block trades carried out pursuant to the Issuer's at-the-market offering facility for which A.G.P./Alliance Global Partners serves as sales agent. The source of funds used to acquire all such Ordinary Shares was the personal funds of the Reporting Person.
Item 5.	Interest in Securities of the Issuer
(c)	Paragraph (c) of Item 5 of Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Person's purchases of (i) 800,000 Ordinary Shares on August 4, 2026, at a weighted average price of $0.50 per share (for aggregate consideration of approximately $400,000), and (ii) 460,000 Ordinary Shares on August 11, 2026, at a price of $0.635 per share (for aggregate consideration of $292,100), were made through block trades carried out pursuant to the Issuer's at-the-market offering facility, for which A.G.P./Alliance Global Partners serves as sales agent. Prior to the August 4, 2026 purchases, the Reporting Person held 83,886 Ordinary Shares directly (excluding shares underlying exercisable options).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

RECANATI LEON

Signature:	/s/ Leon Recanati
Name/Title:	Leon Recanati
Date:	09/11/2026